Trial · NCT02112838
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24 | Baseline to 24 weeks | mg/g | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Mesangial Hypercellularity (M) on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | mesangial hypercellularity score | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Subjects With ≥50% Reduction in sPCR From Baseline (Visit 2) at Week 24 (Visit 9). | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Subjects With ≥ 30% Reduction in Proteinuria From Baseline (Visit 2) at 24 Weeks (Visit 9). | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Endocapillary Hypercellularity (E) on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | Percentage of glomeruli | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Segmental Sclerosis/Adhesion (S) on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | Percentage of glomeruli | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Global Glomerulosclerosis Score on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | Percentage of glomeruli | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Tubulointerstitial Scarring (T) on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | Percentage of glomeruli | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Cellular/Fibrocellular Crescent Score on Renal Biopsies. | Baseline to Week 24 | Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected. | Percentage of glomeruli | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline (Visit 2) of eGFR at 12 Weeks (Visit 7). | Baseline to Week 12 | Analysis population includes only subjects who completed visits through Week 12. | eGFR (mL/min/1.73 m2) | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline (Visit 2) of eGFR at 24 Weeks (Visit 9). | Baseline to Week 24 | eGFR (mL/min/1.73 m2) | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Change From Baseline (Visit 2) of Proteinuria at 12 Weeks (Visit 7). | Baseline to Week 12 | mg/g | LEAST_SQUARES_MEAN | |
| SECONDARY | Percentage of Subjects With sPCR <50 mg/mmol (500 mg/g) at 12 Weeks (Visit 7). | Baseline to Week 12 | percentage of subjects | NUMBER | |
| SECONDARY | Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 12 Weeks (Visit 7). | Baseline to Week 12 | subjects | NUMBER | |
| SECONDARY | Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 24 Weeks (Visit 9). | Baseline to Week 24 | subjects | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02112838/outcomes